TICKERNERD
Menu
DAREDAREHealthcare · Biotechnology

DARE Stock Forecast: Daré Bioscience, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.82
+1.32% on the day

The 3 Wall Street analysts covering Daré Bioscience, Inc. hold a median 12-month price target of $8 — +875.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$15.9M
Ticker Nerd rank
28 / 100
Median analyst target
$8.00
Analysts covering
3
Total return, dividends reinvested
1W
−11.8%
1M
−34.4%
YTD
−57.5%
1Y
−61.0%
From 52W high
−74.9%
From 52W low
+6.8%
$0.77
$3.27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DARE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Daré Bioscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
90
Revisions
88
Issuance
50
Quality
31
Volatility
27
Value
27
Accruals
19
Momentum
14
Growth
8

Size (90): Smaller than most of the companies we track.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DARE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DARE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26DAREHigh $12.00Median $8.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $5.00Median $8.00High $12.00

The green dot is the last close — the median target sits +875.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Dec 2025HC Wainwright & Co.ReiteratesBuy$12
4 Sept 2025Maxim GroupUpgradeBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
17 Dec 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2024HC Wainwright & Co.ReiteratesBuy—
16 Aug 2024Jones TradingMaintainsBuy—
14 Aug 2024Maxim GroupDowngradeHold—
15 May 2024Brookline CapitalUpgradeBuy—
15 May 2024HC Wainwright & Co.ReiteratesBuy—
1 May 2024HC Wainwright & Co.ReiteratesBuy—
17 Apr 2024Brookline CapitalDowngradeHold—
1 Apr 2024HC Wainwright & Co.ReiteratesBuy—
10 Nov 2023HC Wainwright & Co.MaintainsBuy—
11 Aug 2023HC Wainwright & Co.ReiteratesBuy—
13 July 2023HC Wainwright & Co.ReiteratesBuy—
6 June 2023HC Wainwright & Co.ReiteratesBuy—
22 May 2023HC Wainwright & Co.ReiteratesBuy—
12 May 2023HC Wainwright & Co.ReiteratesBuy—
31 Mar 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DARE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

DARE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Daré Bioscience, Inc. (DARE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
11.6×

Cheaper than 13% of US stocks

Price / book
16.2×

Cheaper than 7% of US stocks

EV / EBITDA
−0.7×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
−85.1%

Higher than 2% of US stocks

Earnings growth (YoY)
499.6%

Higher than 95% of US stocks

Gross margin
−58.9%

Higher than 2% of US stocks

Operating margin
−1582.5%

Higher than 5% of US stocks

Net margin
71.3%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−471.4%

Higher than 3% of US stocks

Return on assets
−39.3%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DARE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DAREDaré Bioscience, Inc.$15.9M
28
INTSIntensity Therapeutics, Inc.$15.9M
26
HINDVyome Holdings, Inc.$15.8M
60
ADILAdial Pharmaceuticals, Inc.$16.3M
21
CTXRCitius Pharmaceuticals, Inc.$16.5M
20
BIVIBioVie, Inc.$16.5M
22
PTNPalatin Technologies, Inc.$16.5M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Daré Bioscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DARE news & analysis

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

GlobeNewsWire · 18 Aug 2026positive

Daré Bioscience CEO Sabrina Martucci Johnson was named to the Forbes 2026 "50 Over 50: Innovation" list. The recognition comes as the company advances its multi-product women's health strategy across commercialization, clinical development, and first-in-category innovation.

Why it matters — A DARE watcher would see this national recognition as notable external validation of the company's leadership and its women's health strategy.

Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewsWire · 14 Aug 2026neutral

Daré Bioscience announced pricing of a $6.0 million registered direct offering, selling 4,379,581 shares of common stock (or pre-funded warrants in lieu thereof) to institutional investors at $1.37 per share, priced at-the-market under Nasdaq rules. Each pre-funded warrant is exercisable at $0.0001 per share and expires when exercised in full.

Why it matters — A DARE watcher would care because this offering represents new capital raised by the company through the sale of common stock and pre-funded warrants to institutional investors.

Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

Seeking Alpha published the transcript of Daré Bioscience, Inc.'s (DARE) Q2 2026 earnings call. The transcript covers the company's second-quarter 2026 financial results and management commentary.

Why it matters — A DARE watcher would care because the earnings call transcript provides direct insight into the company's latest quarterly performance and management's outlook.

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 13 Aug 2026positive

Dare Bioscience reported a second-quarter loss of $0.20 per share, which was narrower than the Zacks Consensus Estimate of a $0.33 loss and an improvement over the $0.45 per share loss reported a year earlier. The company's quarterly loss beat revenue expectations.

Why it matters — A narrower-than-expected quarterly loss and improved year-over-year results signal progress for DARE watchers tracking the company's financial trajectory.

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances

GlobeNewsWire · 13 Aug 2026positive

Daré Bioscience reported its second quarter 2026 results and highlighted a commercial inflection as its multi-product women's health strategy advances. The company launched Flora Sync LF5, its first directly commercialized product, which began generating revenue in July.

Why it matters — This marks Daré's transition to directly commercializing its own product and the start of revenue generation, a significant milestone for DARE watchers tracking the company's shift from development to commercialization.

FAQ

Frequently asked questions about DARE stock

What is the DARE stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Daré Bioscience, Inc. have a median 12-month price target of $8, with estimates ranging from $5 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DARE stock a buy right now?

Of the 3 analysts covering Daré Bioscience, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Daré Bioscience, Inc. 28 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DARE?

As at 22 Aug 2026, Daré Bioscience, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will DARE stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +875.7% from the last close, and Ticker Nerd's factor model ranks Daré Bioscience, Inc. 28 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DARE stock forecast for 2030?

No analyst covering Daré Bioscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DARE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $12 over the next 12 months.

How has DARE stock performed over the past year?

Daré Bioscience, Inc. returned -61.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Daré Bioscience, Inc. do?

Dare Bioscience Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products in women's reproductive health.

What is the latest news on DARE?

The most recent item we track (GlobeNewsWire, 18 Aug 2026): "DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List". Daré Bioscience CEO Sabrina Martucci Johnson was named to the Forbes 2026 "50 Over 50: Innovation" list. The recognition comes as the company advances its multi-product women's health strategy across commercialization, clinical development, and first-in-category innovation.

Company

About Daré Bioscience, Inc.

Dare Bioscience Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products in women's reproductive health. The company advances a portfolio of differentiated therapies aimed at contraception, fertility, and related conditions, prioritizing women's health and expanding treatment options. Key products in development include Ovaprene, a hormone-free monthly contraceptive ring, and Topical Sildenafil, a treatment for female sexual dysfunction. Operating within the health technology sector, specifically pharmaceuticals, Dare Bioscience Inc. engages in identifying, developing, and bringing innovative solutions to market that address unmet needs in women's health and well-being. Founded in 2005 and headquartered in San Diego, California, the company plays a role in advancing specialized therapies in the reproductive health market.

CEO Ms. Sabrina Martucci Johnson · 21 employees · United States · https://darebioscience.com